Company / Return on Equity (ROE)
LENZ Therapeutics, Inc. Return on Equity (ROE) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-28.9%
FY2025
5-year range
-28.9% / -18.4%
FY2021-FY2025
Trend
-18.4%
vs FY2024
Sector context
#94 of 190
Health Care
What the data says
LENZ Therapeutics, Inc. reports negative total equity of -28.9% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-28.9% in FY2025.
Declined from -18.4% to -28.9% over the past 4 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#94 of 190 in Health CareTop 49% of 190This company -28.9% Sector average -50.3%
▼
+42.6% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 18.4% year-over-year.
- Currently 21.4pp above the Health Care sector average.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.71 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -28.9% | -18.4% |
| FY2024 | -24.4% | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | -18.4% | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026